Related references
Note: Only part of the references are listed.Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-N-Acetylglucosamine-6-Sulfatase in Neonatal Mice
Feng Wang et al.
MOLECULAR PHARMACEUTICS (2021)
Efficient Interleukin-21 Production by Optimization of Codon and Signal Peptide in Chinese Hamster Ovarian Cells
Hee Jun Cho et al.
JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY (2019)
Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments
Kazuki Sawamoto et al.
DRUGS (2019)
A comprehensive review of signal peptides: Structure, roles, and applications
Hajar Owji et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2018)
Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy
Yonghong Chen et al.
MOLECULAR THERAPY (2018)
Subcellular Trafficking of Mammalian Lysosomal Proteins: An Extended View
Catherine Staudt et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives
Melani Solomon et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Overcoming the Refractory Expression of Secreted Recombinant Proteins in Mammalian Cells through Modification of the Signal Peptide and Adjacent Amino Acids
Gulin Guler-Gane et al.
PLOS ONE (2016)
Enhanced recombinant factor VII expression in Chinese hamster ovary cells by optimizing signal peptides and fed-batch medium
Lin Peng et al.
BIOENGINEERED (2016)
First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient
Joyce E. Fox et al.
MOLECULAR GENETICS AND METABOLISM (2015)
Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations
Shunji Tomatsu et al.
EXPERT OPINION ON ORPHAN DRUGS (2015)
Optimization of Heavy Chain and Light Chain Signal Peptides for High Level Expression of Therapeutic Antibodies in CHO Cells
Ryan Haryadi et al.
PLOS ONE (2015)
Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB
Shih-hsin Kan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Optimized signal peptides for the development of high expressing CHO cell lines
Lars Kober et al.
BIOTECHNOLOGY AND BIOENGINEERING (2013)
A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA
Nicolina Cristina Sorrentino et al.
EMBO MOLECULAR MEDICINE (2013)
Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)
Young Bae Sohn et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Mannose-6-phosphate pathway: A review on its role in lysosomal function and dysfunction
Maria Francisca Coutinho et al.
MOLECULAR GENETICS AND METABOLISM (2012)
Glycosaminoglycan Storage Disorders: A Review
Maria Francisca Coutinho et al.
BIOCHEMISTRY RESEARCH INTERNATIONAL (2012)
Sorting of lysosomal proteins
Thomas Braulke et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2009)
The level of synthesis and secretion of Gaussia princeps luciferase in transfected CHO cells is heavily dependent on the choice of signal peptide
Stian Knappskog et al.
JOURNAL OF BIOTECHNOLOGY (2007)
A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)
Joseph Muenzer et al.
MOLECULAR GENETICS AND METABOLISM (2007)
Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
P Harmatz et al.
JOURNAL OF PEDIATRICS (2004)
Enzyme-replacement therapy in mucopolysaccharidosis I.
ED Kakkis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)